Amgen Enbrel Injects Marketing Push: DTC Effort Counters Humira Launch
Executive Summary
Amgen is planning an aggressive marketing push for Enbrel in response to Abbott's recently approved rheumatoid arthritis biologic Humira
You may also be interested in...
Amgen Enbrel Focus Includes Push For Earlier Treatment Of RA Patients
Amgen's marketing strategy for Enbrel (etanercept) includes closing the gap between diagnosis and initiation of therapy in patients with moderate rheumatoid arthritis
Amgen Enbrel Focus Includes Push For Earlier Treatment Of RA Patients
Amgen's marketing strategy for Enbrel (etanercept) includes closing the gap between diagnosis and initiation of therapy in patients with moderate rheumatoid arthritis
Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy
Abbott will highlight Humira dosing convenience, efficacy and price to encourage switching of rheumatoid arthritis patients from Amgen/Wyeth's Enbrel or Johnson & Johnson's Remicade